Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme

Core Insights - Novo Nordisk presented phase 3 REDEFINE 1 trial data for cagrilintide, a long-acting amylin analogue, at the EASD congress 2025, highlighting its efficacy and safety for weight management in adults with obesity or overweight without diabetes [1][2][4] Group 1: Efficacy and Safety of Cagrilintide - Cagrilintide demonstrated an average body weight reduction of 11.8% after 68 weeks, compared to 2.3% with placebo, with 31.6% of participants achieving ≥15% weight loss versus 4.7% for placebo [1][4] - The treatment was well-tolerated, with gastrointestinal side effects being the most common, primarily mild to moderate, and leading to permanent discontinuation in 1.0% of participants compared to 0.1% for placebo [1][4] Group 2: Future Development and Research - A dedicated phase 3 RENEW programme is set to investigate the efficacy and safety of cagrilintide in individuals with obesity or overweight, scheduled to start in Q4 2025 [1][3] - The data from the REDEFINE 1 trial represents the first phase 3 clinical trial results for a long-acting amylin analogue monotherapy for obesity management, indicating a new treatment avenue [1][2]